Programmed self-assembly of peptide-major histocompatibility complex for antigen-specific immune modulation

Area of Science:

• Immunology
• Biotechnology
• Molecular Biology

Background:

• Developing effective vaccination strategies for challenging diseases like cancer and infectious diseases requires precise T cell population priming.
• Current methods often struggle with T cells exhibiting low avidity against target antigens.

Purpose of the Study:

• To develop a novel technology for priming T cells, particularly those with low avidity, for enhanced immune responses.
• To investigate the potential of programmed self-assembly of peptide-major histocompatibility complex (pMHC) on T cell membranes.

Main Methods:

• Utilized protein annexin V (ANXA5) engineered to link with pMHC.
• Engineered ANXA5 to engage T cell membranes upon T cell receptor (TCR) signaling initiation.
• Investigated ANXA5's role in stabilizing TCR-pMHC interactions and promoting TCR cross-linking via self-assembly into 2D matrices.

Main Results:

• The ANXA5-pMHC system demonstrated a significant augmentation of lymphocyte activation (>1,000-fold).
• The technology bypassed the need for traditional costimulatory signals.
• Successfully broke tolerance against a model self-antigen in vivo.

Conclusions:

• The developed technology enables positive feedback-driven, programmed self-assembly of pMHC on T cells.
• This approach offers a powerful new platform for synthetic immune modulation and advanced vaccination design.
• Opens avenues for treating intractable infectious diseases and cancers through enhanced T cell responses.